Alfred 🏄🏻♀️@HealthyAlfred
Retatrutide reduces body fat by 24% in 24 weeks while PRESERVING muscle mass.
Not Ozempic. Not Mounjaro.
This is a triple agonist: GLP-1 + GIP + glucagon receptor.
Clinical trial, 48 weeks:
• Body weight: -24.2% average
• Fat loss: significant
• Lean muscle mass: PRESERVED
• Metabolic markers: dramatically improved
Here’s why this is different:
Ozempic/Mounjaro = dual agonists (GLP-1 + GIP)
→ Suppress appetite
→ You eat less
→ Lose weight but also muscle
Retatrutide = adds glucagon receptor
→ Suppresses appetite AND
→ Activates fat burning directly
→ Body uses fat for fuel instead of breaking down muscle
Blood work improvements tracked in trials:
• Fasting glucose: normalized
• Triglycerides: -40%
• Inflammatory markers: reduced
• Insulin sensitivity: significantly improved
The metabolic difference:
Dual agonists: Force you to eat less (suffer through hunger, lose muscle)
Retatrutide: Reprograms metabolism to PREFER burning fat (appetite controlled, muscle preserved)
DEXA scans in the study confirmed: Fat mass dropped dramatically. Lean mass stayed intact.
This isn’t starvation weight loss.
This is your body finally burning stored fat the way it’s supposed to.
Typical dosing protocol: Start 2mg weekly, titrate up to 8-12mg based on tolerance.
Compare the outcomes:
• Ozempic: 15% weight loss, muscle loss common, nausea frequent
• Retatrutide: 24% fat loss, muscle preserved, better tolerance profile
One forces calorie restriction.
The other fixes fat metabolism.
